Investor Relations



Corporate Profile

Ocugen, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug — “one to many,” and our novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-developing Bharat Biotech’s COVAXIN™ vaccine candidate for COVID-19 in the U.S. and Canadian markets.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

There are no events scheduled at this time.

Contact Information

Ken Inchausti
Head of Investor Relations & Communications

Receive Email Alerts Email alert icon

Sign up here to receive email alerts whenever Ocugen, Inc. posts new information on the site. Just enter your email address and click Submit.